---
title: "Eton Pharmaceuticals | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 37.59 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295875116.md"
datetime: "2026-08-14T02:57:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295875116.md)
  - [en](https://longbridge.com/en/news/295875116.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295875116.md)
generator: "portal-rs"
---

# Eton Pharmaceuticals | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 37.59 M

Revenue: As of FY2026 Q2, the actual value is USD 37.59 M, beating the estimate of USD 27.12 M.

EPS: As of FY2026 Q2, the actual value is USD 0.35, beating the estimate of USD 0.105.

EBIT: As of FY2026 Q2, the actual value is USD 12.73 M.

Eton Pharmaceuticals, Inc.’s Form 8-K filing dated August 13, 2026, announcing its second quarter financial results for the period ended June 30, 2026, does not include detailed financial and operational metrics such as revenue, net income, gross margin, operating profit, operating costs, cash flow, or specific segment data within the document itself. These detailed results are indicated to be available in an attached Exhibit 99.1, which is a press release. 

#### Non-GAAP Financial Measures

Eton Pharmaceuticals, Inc. presents Adjusted EBITDA as a non-GAAP financial measure to provide a consistent comparison of performance across reporting periods by excluding items not indicative of core operating performance. Management utilizes Adjusted EBITDA for various purposes, including planning, evaluating business strategies, communicating with the board and investors, assessing acquisitions, and evaluating comparative net sales performance. The company believes that Adjusted EBITDA offers analysts and investors a more comprehensive understanding of its operations by providing a metric that is less influenced by financing, accounting methods, asset book values, tax jurisdictions, and capital structures. 

#### Outlook / Guidance

The provided reference does not contain any forward-looking statements, outlook, or guidance regarding future financial performance or operational expectations.

### Related Stocks

- [ETON.US](https://longbridge.com/en/quote/ETON.US.md)

## Related News & Research

- [Major Insider Move at Eton Pharmaceuticals Shakes Up Investor Buzz](https://longbridge.com/en/news/296561958.md)
- [Eton Pharma President and CEO Sean Brynjelsen sells USD 6.19 million in common shares](https://longbridge.com/en/news/296542074.md)
- [Eaton Slips on Acceptance of Technology](https://longbridge.com/en/news/296501214.md)
- [ETON: Record Q2 revenue and raised 2026 guidance reflect strong rare disease portfolio momentum](https://longbridge.com/en/news/295841094.md)
- [Eton Pharma COO Danka Radosavljevic files initial beneficial ownership statement](https://longbridge.com/en/news/295709440.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**